B&M European Value Retail (BME) Q1 2027 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 TU earnings summary
15 Jul, 2026Executive summary
Group revenue grew 2.0% year-over-year in Q1 FY27, led by strong performance in France and positive sales from Heron Foods.
B & M UK saw a like-for-like sales decline of 2.3% due to a slower garden season, but general merchandise returned to growth in May and June.
Inventory discipline and effective clearance resulted in normal seasonal stock levels exiting the garden season.
Financial highlights
Group revenue reached £1,433m, up 2.0% year-over-year.
B & M UK revenue was £1,135m (+0.3% YoY), B & M France £156m (+14.6% YoY), Heron Foods £142m (+2.8% YoY).
B & M France like-for-like sales rose 5.3%; Heron Foods like-for-like sales increased 2.6%.
Outlook and guidance
General merchandise trading margin in the UK continued its upward trend, expected to improve further with new collections.
Ongoing focus on cost mitigation and SKU rationalisation to support profitability recovery.
Latest events from B&M European Value Retail
- Profit growth, £151m special dividend, and raised EBITDA guidance highlight strong performance.BME
Q3 2025 TU8 Jul 2026 - Resilient profit and revenue growth achieved despite negative like-for-likes and cost pressures.BME
H2 20258 Jul 2026 - Revenue and EBITDA up on store growth; outlook and dividend policy raised despite one-offs.BME
H1 20258 Jul 2026 - Q1 revenue up 2.4% to £1,345m, with strong France growth and robust UK margins.BME
Q1 2025 TU8 Jul 2026 - Adjusted EBITDA £459m, revenue up 3.6%, strong cash flow, France outperformed, UK margin pressures.BME
H2 20268 Jul 2026 - Revenue up 10.1% to £5.5bn, with strong EBITDA, cash flow, and accelerated store growth.BME
H2 202431 Jan 2026 - EBITDA guidance cut to £440m–£475m as price investments and clearance weigh on margins.BME
Q3 2026 TU22 Jan 2026 - Q1 revenue up 4.4% to £1.4bn; margin recovery and business plan update expected at H1.BME
Q1 2026 TU13 Nov 2025 - Revenue up 4%, profits and margins down; turnaround plan and leadership changes underway.BME
H1 202613 Nov 2025